Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2000

Ganly I, Kirn D, Eckhardt G, Rodriguez G I, Soutar D S, Otto R, Robertson A G, Park O, Gulley M L, Heise C, Von Hoff D D, Kaye S B, Eckhardt S G

Abstract excerpt

An E1B 55 kDa gene-deleted adenovirus, Onyx-015, which reportedly selectively replicates in and lyses p53-deficient cells, was administered by a single intratumoral injection to a total of 22 patients with recurrent head and neck cancer. The objectives of this Phase I study were to determine the safety, feasibility, and efficacy of this therapy and determine any correlation to p53 status. Six cohorts were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviruses, Human
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibody Formation

Share to Cytopathogenic Effect, Viral

Share to Defective Viruses

Share to Head and Neck Neoplasms

Share to Nausea

Source

Identifiers

PMID: 10741699

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.PMID 10741699Read ↗

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.Semantic proximity Read ↗

Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.Semantic proximity Read ↗

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.Semantic proximity Read ↗

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.Semantic proximity Read ↗

Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian CancerSemantic proximity Read ↗

ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirusSemantic proximity Read ↗

The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma.Semantic proximity Read ↗

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.Semantic proximity Read ↗

Adenoviral gene therapy in head and neck cancer.Semantic proximity Read ↗

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.Semantic proximity Read ↗

Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.Semantic proximity Read ↗

Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.